| Outcome Measures: |
Primary: Number of Participants Who Had One or More Adverse Events, An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment., 36 months|Number of Participants Who Had One or More Adverse Drug Reactions, An adverse event (AE) is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Adverse drug reaction refers to AE related to administered drug., 36 months | Secondary: Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c), The reported data was the change in the mean value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected between baseline and timepoints (up to final assessment point: Month 36). A negative change from baseline indicates improvement., Baseline, up to final assessment point (up to Month 36)|Change From Baseline in Fasting Blood Glucose, The reported data was the change in the mean value of fasting blood glucose collected between baseline and timepoints (up to final assessment point: Month 36). A negative change from baseline indicates improvement., Baseline, up to final assessment point (up to Month 36)|Change From Baseline in Fasting Insulin Level, The reported data was the change in the mean value of fasting insulin level collected between baseline and timepoints (up to final assessment point: Month 36)., Baseline, up to final assessment point (up to Month 36)|Change From Baseline in Homeostasis Model Assessment of Beat-cell Function (HOMA-beta), The reported data was the change in the mean value of HOMA-beta. HOMA-beta measures as following; HOMA-beta = fasting insulin (microU/mL) ×360/ \[fasting glucose (mg/dL) - 63\]., Baseline, up to final assessment point (up to Month 36)|Change From Baseline in Fasting Glucagon, The reported data was the change in the mean value of fasting glucagon collected between baseline and timepoints (up to final assessment point: Month 36)., Baseline, up to final assessment point (up to Month 36)|Percentage of Participants Achieving Good Glycemic Control (Reduction in HbA1c Values < 8.0 Percent), The reported data was percentage of participants who achieved good glycemic control (defined as reduction in HbA1c values \< 8.0 Percent) at baseline and timepoints (up to final assessment point: Month 36)., Baseline, up to final assessment point (up to Month 36)|Percentage of Participants Achieving Good Glycemic Control (Reduction in HbA1c Values < 7.0 Percent), The reported data was percentage of participants who achieved good glycemic control (defined as reduction in HbA1c values \< 7.0 Percent) at baseline and timepoints (up to final assessment point: Month 36)., Baseline, up to final assessment point (up to Month 36)|Percentage of Participants Achieving Good Glycemic Control (Reduction in HbA1c Values < 6.0 Percent), The reported data was percentage of participants who achieved good glycemic control (defined as reduction in HbA1c values \< 6.0 Percent) at baseline and timepoints (up to final assessment point: Month 36)., Baseline, up to final assessment point (up to Month 36)
|
